380 participants
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2024-09-26
- Completion:
- 2029-03-31
Conditions
- NSCLC Patients With Brain Metastasis
Interventions
- DRUG
No Results Yet